Pacira BioSciences' EPS (Weighted Average and Diluted) rose 103.86% to $0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.46, marking a year-over-year increase of 122.89%. This contributed to the annual value of -$2.15 for FY2024, which is 341.57% down from last year.
As of Q3 2025, Pacira BioSciences' EPS (Weighted Average and Diluted) stood at $0.12, which was up 209.09% from -$0.11 recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' EPS (Weighted Average and Diluted) ranged from a high of $0.52 in Q4 2023 and a low of -$3.11 during Q3 2024.
Its 3-year average for EPS (Weighted Average and Diluted) is -$0.11, with a median of $0.19 in 2024.
Per our database at Business Quant, Pacira BioSciences' EPS (Weighted Average and Diluted) surged by 1,250.00% in 2023 and then crashed by 1,452.17% in 2024.
Quarterly analysis of 5 years shows Pacira BioSciences' EPS (Weighted Average and Diluted) stood at -$0.11 in 2021, then crashed by 100.00% to -$0.22 in 2022, then skyrocketed by 336.36% to $0.52 in 2023, then crashed by 32.69% to $0.35 in 2024, then surged by 103.86% to $0.12 in 2025.
Its EPS (Weighted Average and Diluted) stands at $0.12 for Q3 2025, versus -$0.11 for Q2 2025 and $0.10 for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value